adalimumab Archives

MiGenTra phase I German trial for first African developed mAb – biosimilar adalimumab

by Bioblast Editor | Mar 6, 2023 | Biosimilars updates

MiGenTra, a German healthcare transforming company, announced the commencement of the German phase I trial of Minapharm Pharmaceuticals’ African developed adalimumab biosimilar (Adessia®) on 24 February 2023. Results are expected at the end of 2023. MiGenTra was...

Enzene Biosciences begins supply of Humira® (adalimumab) biosimilar in India

by Bioblast Editor | Feb 28, 2023 | Biosimilars updates

Biospectrum India reported that Enzene Biosciences has launched its adalimumab (biosimilar to AbbVie’s Humira®) in India for the treatment of ankylosis spondylitis and rheumatoid arthritis. Enzene believes that this is the first commercial launch using continuous...

Delays for Celltrion’s Yuflyma® (adalimumab) biosimilar in US

by Bioblast Editor | Feb 24, 2023 | Biosimilars updates

The Korea Biomedical Review has reported that Celltrion has explained to shareholders the delay in obtaining US approval for its Humira® adalimumab biosimilar Yuflyma®. Despite obtaining EMA approval in December 2020, Celltrion confirmed that FDA took issue with...

AbbVie sued by Dutch group over Humira® pricing

by Bioblast Editor | Feb 22, 2023 | Biosimilars updates

The Financial Times has reported that the Dutch Pharmaceutical Accountability Foundation (PAF), a public interest group, is suing Abbvie for allegedly overcharging citizens for Humira® (adalimumab) in Holland. PAF is arguing that the pricing of the drug is in breach...

Biora publishes results of PGN-OB1

by Bioblast Editor | Feb 16, 2023 | Biosimilars updates

Biora Therapeutics announced preliminary results from preclinical testing of PGN-0B1, reporting an average bioavailability greater than 50% for a variant of adalimumab. Biora’s systemic therapeutics platform uses an ingestible capsule for needle-free, oral delivery of...